Merck Receives Positive EU Chmp Opinion for Keytruda® (Pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (Mpm)
默沙東收到歐盟藥品評審委員會對Keytruda®（帕博利珠單抗）與化療聯合作爲不可切除非上皮型惡性胸膜間皮瘤（Mpm）成人患者一線治療的積極意見
